The spectrum of adverse events in the treatment of multidrug-resistant tuberculosis among people receiving antiretroviral therapy
- Authors: Degtyareva S.Y.1, Zimina V.N.1,2, Pokrovskaya A.V.1,3, Konovalova A.A.4, Volchenkov G.V.5
-
Affiliations:
- Peoples' Friendship University of Russia
- National Medical Research Center for Phthisiopulmonology and Infectious Diseases
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
- H-Clinic University Clinic
- Center for Specialized Phthisiopulmonological Care
- Issue: Vol 11, No 2 (2021)
- Pages: 100-105
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/287754
- DOI: https://doi.org/10.18565/epidem.2021.11.2.100-5
- ID: 287754
Cite item
Abstract
Full Text
About the authors
Svetlana Yu. Degtyareva
Peoples' Friendship University of Russia
Email: svet@mail.ru
Assistant Lecturer, Department of Infectious Diseases with Courses in Epidemiology and Phthisiology, Medical Institute
Vera N. Zimina
Peoples' Friendship University of Russia; National Medical Research Center for Phthisiopulmonology and Infectious Diseases
Email: vera-zim@yandex.ru
MD, Professor, Department of Infectious Diseases with Courses in Epidemiology and Phthisiology; Leading Researcher
Anastasia V. Pokrovskaya
Peoples' Friendship University of Russia; Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being
Email: pokrovskaya_av@mail.ru
Cand. Med. Sci., Senior Researcher; Associate Professor, Department of Infectious Diseases with Courses in Epidemiology and Phthisiology, Medical Institute
Anastasia A. Konovalova
H-Clinic University Clinic
Email: konovalova@h-clinic.ru
Infectiologist
Grigory V. Volchenkov
Center for Specialized Phthisiopulmonological Care
Email: root@tubdisp.elcom.ru
Head Doctor
References
- WHO. WHO report on the proposed post-2015 TB Strategy and targets, 2013. https://apps.who.int/gb/ebwha/pdf_files/EB134/ B134_12-en.pdf?ua=1
- van den Hof S., Tursynbayeva A., Abildaev T., Adenov M., Pak S., Ismailov S. HIV and multidrug-resistant tuberculosis: overlapping risk factors. Eur. Res. J. 2015; 45: 567-9. doi: 10.1183/09031936.00131014
- Wells C.D., Cegielski J.P., Nelson L.J., Laserson K.F., Holtz T.H., Finlay A. et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J. Infect. Dis. 2007; 196 (Suppl 1): S86-107.
- WHO. Global tuberculosis report 2019. 2019, 103 р. https://apps. who.int/ iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1
- Chem E.D, Van Hout M.C., Hope V. Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis. BMC Infect. Dis. 2019; 19(1): 723. doi:10.1186/ s12879-019-4317-4
- WHO. WHO consolidated guidelines on drug resistant tuberculosis treatment. 2019. 28 р. https://www.who.int/tb/publications/2019/ consolidated-guidelines-drug-resistant-TB-treatment/en/
- EACS. Guidelines, version 10.0, November 2019. 20 р. https:// www. eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines. html
- Российское общество фтизиатров. Федеральные клинические рекомендации по лечению туберкулеза у больных ВИЧ-инфекцией. 2016; 20. http://roftb.ru/netcat_files/ doks2016/rec2016.pdf
- Pandie M., Wiesner L., McIlleron H., Hughes J., Siwendu S., Conradie F. et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J. Antimicrob. Chemother. 2016; 71(4): 1037-40.
- Dooley K.E., Park J.G., Swindells S., Allen R., Haas D.W., Cramer Y. et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J. Acquir. Immune Defic.Syndr. 2012; 59(5): 455- 62.
- Mallikaarjun S., Wells C., Petersen C. , Paccaly A., Shoaf S.E., Patil S. et al. Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug-drug interactions in healthy subjects. Antimicrob. Agents Chemother. 2016; 60(10): 5976-85.
- Дегтярева С.Ю., Белобородова Е.Н., Покровская А.В., Климова Ю.А., Викторова И.Б., Зимина В.Н. Безопасность терапии туберкулеза с множественной лекарственной устойчивостью возбудителя у больных ВИЧ-инфекцией, получающих антиретровирусную терапию. Туберкулез и болезни легких 2019; 97(3): 46-53.
- Российское общество фтизиатров. Федеральные клинические рекомендации по диагностике и лечению туберкулеза у больных ВИЧ-инфекцией, 2014. http://roftb.ru/netcat_files/ doks2015/rec4.pdf
- Национальное научное общество инфекционистов. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2014; 6(приложение)
- Arentz M., Pavlinac P., Kimerling M.E., Horne D.J., Falzon D., Schflnemann H.J. et al. Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. PLoS One 2012; 7(11): e47370. doi:10.1371/ journal.pone.0047370
- Isaakidis P., Varghese B., Mansoor H., Cox H.S., Ladomirska J., Saranchuk P. et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One. 2012; 7(7): e40781. doi: 10.1371/journal.pone.0040781
- Palmero D., Cruz V., Museli T., Pavlovsky H., Fernindez J., Waisman J. Reacciones adversas a firmacos en tuberculosis multirresistente [Adverse drug reactions in multidrug-resistant tuberculosis]. Medicina (B Aires). 2010; 70(5): 427-33.
- Schnippel K., Berhanu R.H., Black A., Firnhaber C., Maitisa N., Evanse D. et al. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study. BMC Infect. Dis. 2016; 16(1): 593. doi: 10.1186/s12879-016-1933-0
- Shin S.S., Pasechnikov A.D., Gelmanova I.Y., Peremitin G.G., Strelis A.K., Mishustin S. et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int. J. Tuberc. Lung Dis. 2007; 11(12): 1314-20.
- Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2015 (WH0/HTM/TB/2014.11); http://apps.who. int/iris/ bitstream/10665/130918/1/9789241548809_eng.pdf